Health Economic Analysis Reports That Revlimid is a Cost Effective - Forbes
Celgene International Sarl (Nasdaq:CELG) announced that data presented today at the 13th Congress of the European Hematology Association (EHA) in Copenhagen, Denmark found that patients previously treated for multiple myeloma receiving REVLIMID
Source: www.forbes.com

Blood test may detect cancer - Ksee24.com
Comments are moderated and will not appear on this story until after they have been reviewed and deemed appropriate for posting. KSEE 24 NEWS and its affiliated companies are not responsible for the content of comments posted or for anything arising
Source: www.ksee24.com